^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 expression

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    23h
    Cytotoxic and immunomodulatory activity of CD151-LEL-based peptides in breast cancer and THP-1 cells. (PubMed, Hum Immunol)
    Furthermore, conditioned media from the treated BC cells induced the proliferation of PMA treated monocyte like THP-1 cells and provoked the secretion of IL-6, while reducing IL-10. These findings suggest that the CD151-LEL-based peptides and their engineered multiepitope construct represent a prospective vaccine candidate for in vivo experimental validation, which can be used as a therapeutic vaccine for breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • TLR2 (Toll Like Receptor 2) • CD151 (CD151 Molecule)
    |
    HER-2 amplification • HER-2 expression
    2d
    Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors (clinicaltrials.gov)
    P1, N=48, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    CCNE1 (Cyclin E1)
    |
    HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • azenosertib (ZN-c3)
    3d
    Predictors of Response to Neoadjuvant Therapy in HER2-positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity. (PubMed, Mod Pathol)
    Higher HER2-HQE is associated with increased RCB. Quantifying HER2 heterogeneity via HQE and percentage of HER2 IHC 3+ may help optimize therapeutic strategies in clinical practice.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    3d
    Clinical characteristics and survival outcomes of young women with luminal HER2-low and HER2-ultralow breast cancer. (PubMed, Cancer Treat Res Commun)
    Approximately 40 % of young women with luminal HER2-negative breast cancers have HER2-low or ultralow disease. These findings highlight the importance of accurately assessing HER2 expression in YWBC to identify candidates for emerging HER2-targeted therapies such as trastuzumab deruxtecan.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    Impact of MET Gene Abnormalities on the Efficacy of Anti-HER2 Targeted Therapy in Chinese Gastric Cancer Patients: A Multicenter, Retrospective Cohort Study (ChiCTR2600117225)
    P=N/A, N=420, Not yet recruiting, Shanghai East Hospital; Shanghai East Hospital
    New trial
    |
    HER-2 expression
    3d
    This study aims to evaluate the efficacy and safety of Disitamab Vedotin combined with Cisplatin and Candelinib in the treatment of patients with locally advanced cervical cancer. (ChiCTR2500114983)
    P=N/A, N=30, Recruiting, Dalian Medical University Second Affiliated Hospital; Dalian Medical University Second Affiliated Hospital
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 expression
    |
    cisplatin • Aidixi (disitamab vedotin) • Kaitanni (cadonilimab)
    3d
    Trastuzumab rezetecan alone or in combination with adebrelimab in advanced solid tumors with HER2 expression or mutation: a prospective, multicenter, open, nonrandomized, multicohort study. (ChiCTR2500113763)
    P=N/A, N=200, Not yet recruiting, The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation • HER-2 expression
    |
    Herceptin (trastuzumab) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    3d
    Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Low Advanced Breast Cancer and Brain Metastases: A Multicenter Retrospective Study (ChiCTR2500113697)
    P=N/A, N=46, Not yet recruiting, The Affiliated Hospital of Inner Mongolia Medical University; The Affiliated Hospital of Inner Mongolia Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression • HER-2 underexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    A prospective, single-arm, exploratory study of RC48 combination therapy in neoadjuvant treatment of HER2-expressing ovarian cancer (ChiCTR2600117491)
    P4, N=20, Not yet recruiting, Liaoning Cancer Hospital; Liaoning Cancer Hospital
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 expression
    |
    Avastin (bevacizumab) • carboplatin
    3d
    Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed high-risk MIBC patients after radical cystectomy: a prospective, multicentre, open-label, randomised, phase 3 trial (ChiCTR2500111817)
    P3, N=128, Recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
    3d
    Disitamab Vedotin combining with Toripalimab versus adjuvant Toripalimab in HER2 expressed locally advanced UTUC patients after nephron-ureterectory: a prospective, multicentre, open-label, randomised, phase 3 trial (ChiCTR2500115471)
    P3, N=106, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
    3d
    Trastuzumab Combined With Chemotherapy and Leflunomide for HER2-Expressing Unresectable Advanced Biliary Tract Malignancies: An Open-Label, Single-Arm, Phase II Study (ChiCTR2500112844)
    P2, N=53, Not yet recruiting, The Third Affiliated Hospital of Naval Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Naval Me
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HER-2 amplification • HER-2 expression • HER-2 underexpression
    |
    Herceptin (trastuzumab) • leflunomide